CTKB
NASDAQCytek Biosciences Inc.
Price$5.26-0.05 (-0.94%)
01:30 PM07:45 PM
News · 26 weeks53-50%
2026-04-192026-10-11
Mix2090d
- Other7(35%)
- Insider7(35%)
- SEC Filings4(20%)
- Earnings2(10%)
Latest news
25 items- SECSEC Form 8-K filed by Cytek Biosciences Inc.8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRCytek® Biosciences Extends Capabilities Within Cytek Cloud Digital Ecosystem with New Cloud Analysis ToolFREMONT, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the expansion of its Cytek® Cloud digital ecosystem with a new Cloud Analysis tool, establishing the industry’s first end-to-end platform that integrates the entire flow cytometry workflow from panel design to data analysis into one system. Cytek Cloud is built by the scientists and engineers behind Cytek Full Spectrum Profiling™ (FSP®) technology and gives researchers a consistent experience from experiment planning through data analysis while reducing the need to move between systems or recreate work along the way. Historically, moving from data acqu
- PRSysmex Europe and Cytek® Biosciences Collaborate to Expand Access to Advanced Clinical Flow CytometryFREMONT, Calif., and HAMBURG, Germany, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sysmex Europe SE, a leader in diagnostic and healthcare solutions, and Cytek Biosciences, Inc. (NASDAQ:CTKB), a leader in spectral flow cytometry technology, today announced a strategic collaboration across over a dozen European countries to enhance clinical flow cytometry workflows and expand access to innovative diagnostic solutions. The collaboration brings together the expertise and technologies of both companies to provide clinical laboratories with a broader portfolio of flow cytometry technologies that improve workflow efficiency, standardization and advanced clinical capabilities. Together, Sysmex and Cytek
- PRCytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCSFREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course. Set apart from traditional flow cytometry approaches, Cytek’s distinctive Full Spectrum Profiling™ (FSP®) technology is helping to expand the possibilities of cell analysis across research and clinical appli
- PRCytek Biosciences to Participate in Upcoming Investor ConferencesFREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (NASDAQ:CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences. Wells Fargo 21st Annual Healthcare Conference in Boston, MACFO William McCombe will be participating in investor meetings on Tuesday, September 8, 2026 Morgan Stanley 24th Annual Global Healthcare Conference in New York, NYCEO Wenbin Jiang and CFO William McCombe will be participating in a fireside chat on Wednesday, September 16, 2026, at 9:15 a.m. Pacific Time / 12:15 p.m. Eastern Time Deutsche Bank’s 2026 Healthcare Summit in New York, NYCEO Wenbin Jian
- SECCytek Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRJury Finds in Cytek’s Favor on Three of Four Asserted Claims; Company to Challenge Remaining FindingFREMONT, Calif., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court for the District of Delaware returned a verdict in the patent infringement action brought by Beckman Coulter, Inc. The jury found in Cytek’s favor on three of the four asserted patent claims, finding noninfringement and invalidity as to each of those three claims. With respect to one claim, the jury found no literal infringement but found infringement under the doctrine of equivalents. The jury awarded past damages consisting of $20 million in lost
- INSIDERPRESIDENT AND CEO Jiang Wenbin converted options into 120,095 shares and covered exercise/tax liability with 36,269 shares, increasing direct ownership by 2% to 5,561,029 units (SEC Form 4) (for withholding tax)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERChief Financial Officer Mccombe William D. converted options into 35,420 shares and covered exercise/tax liability with 11,904 shares, increasing direct ownership by 21% to 134,693 units (SEC Form 4) to satisfy withholding tax4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Muir Glenn P converted options into 3,086 shares (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Holder Michael converted options into 2,181 shares, increasing direct ownership by 4% to 62,875 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERDirector Chin Richard converted options into 6,107 shares, increasing direct ownership by 27% to 28,499 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming converted options into 33,270 shares and covered exercise/tax liability with 8,088 shares, increasing direct ownership by 0.52% to 4,821,870 units (SEC Form 4) (tax withholding)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer, Secretary Feuchtwang Ilan4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Cytek Biosciences Inc.SCHEDULE 13G/A - Cytek Biosciences, Inc. (0001831915) (Subject)
- SECSEC Form 10-Q filed by Cytek Biosciences Inc.10-Q - Cytek Biosciences, Inc. (0001831915) (Filer)
- SECCytek Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- PRCytek Biosciences Reports Second Quarter 2026 Financial ResultsFREMONT, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2026. Recent Highlights Total revenue for the second quarter of 2026 was $48.1 million, representing a 6% increase compared to the second quarter of 2025Launched Cytek Borealis™, a new 7-laser full spectrum flow cytometer with new and proprietary reagents enabling high-resolution 60-color panelsIntroduced Cytek Aurora™ Evo instrument configurations with expanded automation capabilities for highly automated lab environmentsTotal recurring revenue, comprise
- SECSEC Form SCHEDULE 13G filed by Cytek Biosciences Inc.SCHEDULE 13G - Cytek Biosciences, Inc. (0001831915) (Subject)
- PRCytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026FREMONT, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (NASDAQ:CTKB), today announced that it will report financial results for the second quarter of 2026 after market close on Wednesday, August 5, 2026. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at investors.cytekbio.com. About Cytek Biosciences, Inc.Cytek Biosciences (NASDAQ:CTKB) is a leading cell analysis solutions company advancing the next gen
- PRCytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer EngagementFREMONT, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Spectral flow cytometry leader Cytek Biosciences, Inc. (NASDAQ:CTKB) today announced the opening of a new innovation center in Bellevue, Washington, marking the relocation of its previous Seattle-area operations to a dedicated facility designed to support research and development (R&D) while strengthening collaboration and customer engagement. The new site has been renovated to serve as a dedicated hub for innovation and technical excellence. As the sole tenant of the building, Cytek has designed the space to bring together key capabilities under one roof. The facility includes R&D laboratories and dedicated areas for instrument service t
- SECSEC Form 8-K filed by Cytek Biosciences Inc.8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- INSIDERSEC Form 3 filed by new insider Feuchtwang Ilan3 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SECSEC Form 8-K filed by Cytek Biosciences Inc.8-K - Cytek Biosciences, Inc. (0001831915) (Filer)
- INSIDERCHIEF TECHNOLOGY OFFICER Yan Ming gifted 135,892 shares, decreasing direct ownership by 3% to 4,796,688 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
CTKB FAQ
6 questionsWhere does CTKB stock trade?
Cytek Biosciences Inc. (CTKB) is listed on NASDAQ.What sector and industry is CTKB in?
Cytek Biosciences Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Cytek Biosciences Inc. go public?
Cytek Biosciences Inc. (CTKB) completed its IPO in 2021.What are analysts saying about CTKB?
Cytek Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $600.00 price target on 2025-12-02. Recent price targets range from $400.00 to $2000.00.What companies are similar to CTKB?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare CTKB side-by-side with any of them on Quantisnow.How can I track CTKB on Quantisnow?
Quantisnow aggregates Cytek Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTKB to receive live email and push alerts on every new disclosure.